ClinVar Miner

Submissions for variant NM_001250.6(CD40):c.256+2T>C

dbSNP: rs774195387
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories RCV000506361 SCV000602937 pathogenic not specified 2017-03-08 criteria provided, single submitter clinical testing
Baylor Genetics RCV001333032 SCV001525513 pathogenic Hyper-IgM syndrome type 3 2020-06-08 criteria provided, single submitter clinical testing This variant was determined to be pathogenic according to ACMG Guidelines, 2015 [PMID:25741868].
Genomic Medicine Center of Excellence, King Faisal Specialist Hospital and Research Centre RCV004819197 SCV005038860 uncertain significance Hyper-IgM syndrome type 1 2024-03-14 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV001333032 SCV005395101 pathogenic Hyper-IgM syndrome type 3 2024-09-10 criteria provided, single submitter clinical testing Variant summary: CD40 c.256+2T>C is located in a canonical splice-site and is predicted to affect mRNA splicing resulting in a significantly altered protein due to either exon skipping, shortening, or inclusion of intronic material. Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing and loss of CD40 function. Several computational tools predict a significant impact on normal splicing: Two predict the variant abolishes a 5' splicing donor site. One publication reports experimental evidence that this variant results in exon 3 skipping, confirmed by Western blot and sequencing of cDNA from homozygous patients carrying the variant (e.g. Al-Saud_2013). The variant allele was found at a frequency of 4e-06 in 251042 control chromosomes. c.256+2T>C has been reported in the literature in multiple homozygous individuals affected with Hyper IgM Syndrome Type 3 (e.g. Al-Saud_2013). These data indicate that the variant is very likely to be associated with disease. The following publication has been ascertained in the context of this evaluation (PMID: 29884852). ClinVar contains an entry for this variant (Variation ID: 439466). Based on the evidence outlined above, the variant was classified as pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.